© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 161 Farringdon Rd, London EC1R 3AL. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions | Cookies

Equity IPOs

Top Section/Ad

Top Section/Ad

Most recent

More articles/Ad

More articles/Ad

More articles

  • Europe’s IPO market is not broken — deals get done and in some years activity is quite brisk — but it has little to be proud of. The failure rate of deals this year has been stark and the market needs to adapt.
  • Morgan Stanley-backed China Feihe, a producer of infant milk formula, hit the road this week to drum up interest in its Hong Kong listing.
  • UBS Securities has become the first foreign-owned joint venture to sponsor a listing on Shanghai’s Star Market, where underwriters have to invest in the listings they bring to market.
  • SinoMab BioScience, a biopharmaceutical firm, has started taking orders for its up to HK$1.7bn ($223m) Hong Kong IPO.
  • Atos, the French IT services and consulting company, has reduced its exposure to Worldline via an intricate transaction involving a share sale, an exchangeable bond and a private placement of stock. In addition to the sale of shares owned by Atos, SIX Group entered into a collar transaction to hedge its exposure in Worldline.
  • The IPOs of Française des Jeux, the operator of the French national lottery, and DNEG, the UK special effects company, are both gaining strong traction among IPO investors hoping for a strong finish to 2019.